

THE EFFECT OF BLUE METHYLENE TABLETS ON ADENOMA DETECTION IN NEOPLASIA SURVEILLANCE OF PEOPLE WITH LYNCH SYNDROME

Andrea Iannone

UEG Week Berlin 2025

Poster

Colorectal

October 4, 2025

Blue methylene tablets added to standard colonoscopy preparation did not significantly increase adenoma detection rate in Lynch syndrome patients in this preliminary observational study of 38 participants.

KEY POINTS

- The adenoma detection rate was 11.8% in the blue methylene tablet group versus 14.2% in the control group, with no statistically significant difference ($p=0.94$).
- Thirty-eight Lynch syndrome patients were enrolled: 17 received blue methylene tablets (3 tablets the night before, 2 tablets 5 hours before) plus 2 litres of PEG, and 21 received PEG alone.
- The polyp detection rate was 29.4% in the blue methylene group versus 23.8% in controls ($p=0.73$), and the average number of adenomas and polyps per colonoscopy were comparable between groups.
- The two groups were comparable for sex, age, mutation types, and previous polypectomy history, and all patients with previous colonic resections were excluded.
- The authors note that larger studies may be needed to confirm these findings in the Lynch syndrome population, where prior studies showed benefit of blue methylene tablets in average-risk screening populations.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/d3c14306-a813-11f0-a2c0-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.